|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-10-4
|
|
pubmed:abstractText |
Most breast cancer patients with bone metastases will receive bisphosphonate treatment. This post hoc analysis investigated whether early normalization of urinary N-telopeptide of type I collagen (NTX) levels during bisphosphonate therapy correlates with a long-term reduction in skeletal-related event (SRE) risk and mortality in patients with breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1083-7159
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1035-43
|
|
pubmed:meshHeading |
pubmed-meshheading:17914073-Biological Markers,
pubmed-meshheading:17914073-Bone Density Conservation Agents,
pubmed-meshheading:17914073-Bone Neoplasms,
pubmed-meshheading:17914073-Breast Neoplasms,
pubmed-meshheading:17914073-Collagen Type I,
pubmed-meshheading:17914073-Creatinine,
pubmed-meshheading:17914073-Diphosphonates,
pubmed-meshheading:17914073-Female,
pubmed-meshheading:17914073-Follow-Up Studies,
pubmed-meshheading:17914073-Fractures, Bone,
pubmed-meshheading:17914073-Humans,
pubmed-meshheading:17914073-Imidazoles,
pubmed-meshheading:17914073-Injections, Intravenous,
pubmed-meshheading:17914073-Male,
pubmed-meshheading:17914073-Multiple Myeloma,
pubmed-meshheading:17914073-Osteoclasts,
pubmed-meshheading:17914073-Osteolysis,
pubmed-meshheading:17914073-Peptides,
pubmed-meshheading:17914073-Retrospective Studies,
pubmed-meshheading:17914073-Risk Assessment,
pubmed-meshheading:17914073-Survival Rate,
pubmed-meshheading:17914073-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
|
|
pubmed:affiliation |
Milton S. Hershey Medical Center, Penn State Cancer Institute, 500 University Drive, Hershey, Pennsylvania 17033, USA. alipton@psu.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
